Versions :<1 2 3 4 5 6 Live

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

Is expanding GP access to weight-loss drugs a vital health strategy, an opportunity best seized by pharmacies or a dangerous profit-driven scheme?

Published 6 days ago

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

story

Above: A Mounjaro weight-loss jab in Totnes, Devon, on Feb. 20. Image credit: Matthew Horwood/Getty Images

The Spin

Pro-government narrative

This initiative is part of the government's strategy to tackle the burden of obesity on the U.K.'s health services and economy. By encouraging GPs to offer these life-altering medications to the wider public, the government can ensure that those who need this form of treatment, but cannot afford it privately, will receive it with wraparound support.

BBC Breakfast on X

Government-critical narrative

While the NHS's rollout of weight-loss drugs remains painfully slow, with only a handful of patients treated, placing the burden on overstretched GPs is not the answer. The government should instead consider commissioning pharmacies, which can provide the sustainable weight-loss treatment required more quickly than the sluggish NHS system.

National Pharmacy Association

Establishment-critical narrative

This scheme creates dangerous incentives by paying GPs thousands of pounds to prescribe medications without any long-term safety data. With hundreds already dead and injured as a result of these treatments, it is clear that the government is prioritizing corporate profit over patient safety by pushing this medical quackery.

Unity Net News on X

Metaculus Prediction

There's a 50% chance that the reported Q1 2026 global revenue for Mounjaro will be at least $7.1 billion, according to the Metaculus prediction community.